CYTK (Cytokinetics) GF Value Rank: 2 (As of Aug. 04, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYTK Cytokinetics Inc CYTK
51 GF Score
Price $76.45
GF Value $253.62
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cytokinetics GF Value Rank?

Cytokinetics CYTK -0.88% 51 GF Value Rank is 2 as of Aug. 04, 2026, which is 100% above its 10-year median of 1.00. GuruFocus rates CYTK with a GF Score™ of 51/100 and a GF Value™ of $253.62 (Possible Value Trap). The stock has 6 warning signs investors should review.

Cytokinetics has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cytokinetics GF Value Rank Related Terms

CYTK vs SMMT, TECH, BMRN: GF Value Rank Comparison

For the Biotechnology subindustry, Cytokinetics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Cytokinetics's GF Value Rank falls into.


CYTK
51GF Score
Cytokinetics Inc CYTK
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Cytokinetics (CYTK) has a GF Value Rank of 2 as of Aug. 04, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Cytokinetics and its competitors. This is 100% above median its historical median of 1.00. Over the past decade, Cytokinetics' GF Value Rank has ranged from 1.00 to 10.00.
Is Cytokinetics' GF Value Rank too high?
Cytokinetics' current GF Value Rank of 2 is 100% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Cytokinetics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cytokinetics' GF Value Rank compare to SMMT and TECH?
Cytokinetics' GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Cytokinetics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Cytokinetics and its competitors. Cytokinetics's current GF Value Rank is 2, which is 100% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytokinetics stock overvalued right now?
Based on GuruFocus' analysis, Cytokinetics (CYTK) is currently considered Possible Value Trap. The stock's GF Value™ is $253.62, compared to a current price of $76.45 — trading 69.9% below its estimated fair value. The current GF Value Rank is 2, which is 100% above median its 10-year median of 1.00. Cytokinetics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Cytokinetics (CYTK), the current GF Value Rank is 2 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytokinetics (CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of $76.45 is trading 69.9% below its estimated GF Value™ of $253.62. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for CYTK:

  • GF Value Rank: 2 (100% above median its 10-year median of 1.00)
  • GF Value™: $253.62 vs. price of $76.45 (69.9% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytokinetics Business Description

Other Exchanges 1CYTK:ItalyKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
51GF Score

Get the complete analysis for CYTK

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.45
Price
$253.62
GF Value